In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Dual anti-platelet therapy is associated with reduced risk of clinical vasospasm and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage

    Final Number:
    4068

    Authors:
    Y. Nagahama MD; B. Prout BS; L. Allan DO; D. Nakagawa MD; M. Zanaty MD; R. Starke MD MSc; N. Chalouhi MD; P. Jabbour MD; R. Brown Jr, MD; C. Derdeyn MD FACR; E. Leira MD MS; J. Broderick MD; M. Chimowitz MB ChB; J. Torner; D. Hasan MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting - Late Breaking Science

    Introduction: Clinical vasospasm and delayed cerebral ischemia (DCI) are devastating complications of aneurysmal subarachnoid hemorrhage (aSAH). Several theories have been postulated as potential etiologies of clinical vasospasm and DCI, involving platelet activation. However, the effects of dual anti-platelet therapy (DAPT: aspirin and clopidogrel) on clinical vasospasm and DCI have not been previously investigated. The objective of this study was to evaluate the effects of DAPT on clinical vasospasm and DCI in aSAH patients.

    Methods: Analysis of patients treated for aSAH during the period from July 2009 to April 2014 was performed in a single-institution retrospective study. Patients were divided into two groups: patients who underwent stent-assisted coiling or placement of flow diverters requiring DAPT (DAPT group) and patients who underwent coiling only without DAPT (control group). The frequency of symptomatic clinical vasospasm and DCI and of hemorrhagic complications was compared between the two groups, utilizing univariate and multivariate logistic regression.

    Results: Of 312 aSAH patients considered for this study, 161 patients met the inclusion and exclusion criteria and were included in the analysis (85 patients in the DAPT group and 76 patients in the control group). The risks of clinical vasospasm (OR: 0.244; CI 95% [0.097 – 0.615]; p = 0.003) and DCI (OR: 0.056; CI 95% [0.01 – 0.318]; p = 0.001) were significantly lower in patients receiving DAPT. Hemorrhagic complications associated with placement of external ventricular drains and ventriculoperitoneal shunts were similar in both groups (4% versus 2%; p = 0.9).

    Conclusions: The use of DAPT was associated with a lower risk of clinical vasospasm and DCI in patients treated for aSAH without an increased risk of hemorrhagic complications.

    Patient Care: The research presented provides new evidence for lowering the risk of both clinical vasospasm and DCI without increasing the risk of hemorrhagic complications through the use of DAPT in patients following treatment of aSAH.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) In small groups, discuss potential etiologies of clinical vasospasm and DCI, 2) Identify the incidence of clinical vasospasm and DCI in patients following aSAH, 3) Evaluate the effects of DAPT on clinical vasospasm and DCI in aSAH patients.

    References: 1. Ayer R, Zhang J: Connecting the early brain injury of aneurysmal subarachnoid hemorrhage to clinical practice. Turk Neurosurg 20:159-166, 2010 2. Bove AA, Dewey JD: Effects of serotonin and histamine on proximal and distal coronary vasculature in dogs: comparison with alpha-adrenergic stimulation. Am J Cardiol 52:1333-1339, 1983 3. Cohen RA, Shepherd JT, Vanhoutte PM: 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. Am J Physiol 245:H1077-1080, 1983 4. Cohen RA, Shepherd JT, Vanhoutte PM: Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 221:273-274, 1983 5. Dorhout Mees SM, Rinkel GJ, Hop JW, Algra A, van Gijn J: Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 34:2285-2289, 2003 6. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ: Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev:CD006184, 2007 7. Dorsch NW, King MT: A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci 1:19-26, 1994 8. Frijns CJ, Fijnheer R, Algra A, van Mourik JA, van Gijn J, Rinkel GJ: Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatry 77:77-83, 2006 9. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, et al: Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke 40:1963-1968, 2009 10. Hirashima Y, Nakamura S, Endo S, Kuwayama N, Naruse Y, Takaku A: Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 22:1249-1255, 1997 11. Hirashima Y, Nakamura S, Suzuki M, Kurimoto M, Endo S, Ogawa A, et al: Cerebrospinal fluid tissue factor and thrombin-antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage. Stroke 28:1666-1670, 1997 12. Ikeda K, Asakura H, Futami K, Yamashita J: Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage. Neurosurgery 41:344-349; discussion 349-350, 1997 13. Juvela S, Hillbom M, Kaste M: Platelet thromboxane release and delayed cerebral ischemia in patients with subarachnoid hemorrhage. J Neurosurg 74:386-392, 1991 14. Juvela S, Ohman J, Servo A, Heiskanen O, Kaste M: Angiographic vasospasm and release of platelet thromboxane after subarachnoid hemorrhage. Stroke 22:451-455, 1991 15. Kassell NF, Torner JC, Haley EC, Jr., Jane JA, Adams HP, Kongable GL: The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg 73:18-36, 1990 16. Lam JY, Chesebro JH, Steele PM, Badimon L, Fuster V: Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation 75:243-248, 1987 17. le Roux AA, Wallace MC: Outcome and cost of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am 21:235-246, 2010 18. Mathiesen T, Edner G, Ulfarsson E, Andersson B: Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage. J Neurosurg 87:215-220, 1997 19. Neil-Dwyer G, Lang DA, Doshi B, Gerber CJ, Smith PW: Delayed cerebral ischaemia: the pathological substrate. Acta Neurochir (Wien) 131:137-145, 1994 20. Ohkuma H, Suzuki S, Kimura M, Sobata E: Role of platelet function in symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 22:854-859, 1991 21. Ohta H, Ito Z: [Cerebral infraction due to vasospasm, revealed by computed tomography (author's transl)]. Neurol Med Chir (Tokyo) 21:365-372, 1981 22. Osuka K, Suzuki Y, Tanazawa T, Hattori K, Yamamoto N, Takayasu M, et al: Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien) 140:943-951, 1998 23. Peltonen S, Juvela S, Kaste M, Lassila R: Hemostasis and fibrinolysis activation after subarachnoid hemorrhage. J Neurosurg 87:207-214, 1997 24. Romano JG, Forteza AM, Concha M, Koch S, Heros RC, Morcos JJ, et al: Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage. Neurosurgery 50:1026-1030; discussion 1030-1021, 2002 25. Roos YB, de Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M: Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 68:337-341, 2000 26. Rowland MJ, Hadjipavlou G, Kelly M, Westbrook J, Pattinson KT: Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br J Anaesth 109:315-329, 2012 27. Simard JM, Aldrich EF, Schreibman D, James RF, Polifka A, Beaty N: Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment. J Neurosurg 119:1611-1619, 2013 28. Stein SC, Browne KD, Chen XH, Smith DH, Graham DI: Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery 59:781-787; discussion 787-788, 2006 29. Suarez JI, Tarr RW, Selman WR: Aneurysmal subarachnoid hemorrhage. N Engl J Med 354:387-396, 2006 30. Suzuki S, Kimura M, Souma M, Ohkima H, Shimizu T, Iwabuchi T: Cerebral microthrombosis in symptomatic cerebral vasospasm--a quantitative histological study in autopsy cases. Neurol Med Chir (Tokyo) 30:309-316, 1990 31. Suzuki S, Suzuki M, Iwabuchi T, Kamata Y: Role of multiple cerebral microthrombosis in symptomatic cerebral vasospasm: with a case report. Neurosurgery 13:199-203, 1983 32. Vanhoutte PM, Houston DS: Platelets, endothelium, and vasospasm. Circulation 72:728-734, 1985 33. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28:1761-1770, 2008 34. Vinge E, Brandt L, Ljunggren B, Andersson KE: Thromboxane B2 levels in serum during continuous administration of nimodipine to patients with aneurysmal subarachnoid hemorrhage. Stroke 19:644-647, 1988 35. Vora YY, Suarez-Almazor M, Steinke DE, Martin ML, Findlay JM: Role of transcranial Doppler monitoring in the diagnosis of cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 44:1237-1247; discussion 1247-1238, 1999

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy